Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Rituximab 138Bevacizumab 138Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 64Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × ferumoxtran-10 × Clear all
NCT00659334 2022-12-21

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

OHSU Knight Cancer Institute

Phase 2 Terminated
116 enrolled 12 charts
CNS

Brain Neoplasms

NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡